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ABSTRACT  
Prior to updating global influenza-associated mortality estimates, the World Health 
Organization convened a consultation in July 2017 to understand differences in methodology 
and implications on results of three influenza mortality projects from the United States 
Centers for Disease Control and Prevention (CDC), the Netherlands Institute for Health 
Service Research (GLaMOR), and the Institute for Health Metrics and Evaluation (IHME). 
The expert panel reviewed estimates and discussed differences in data sources, analysis, and 
modeling assumptions. We performed a comparison analysis of the estimates. Influenza-
associated respiratory death counts were comparable between CDC and GLaMOR; IHME 
estimate was considerably lower. The greatest country-specific influenza-associated mortality 
rate fold differences between CDC/IHME and between GLaMOR/IHME estimates were 
among countries in South-East Asia and Eastern Mediterranean region. The data envelope 
used for the calculation was one of the major differences (CDC and GLaMOR: all respiratory 
deaths; IHME: low respiratory infection deaths). With the assumption that there is only one 
cause of death for each death, IHME estimates a fraction of the full influenza-associated 
respiratory mortality that is measured by the other two groups. Wide variability of parameters 
was observed. Continued coordination between groups could assist with better understanding 
of methodological differences and new approaches to estimating influenza deaths globally.  
 
Key words: Comaprison, Estimates, Global, Influenza, Mortality 
Abbreviations: AD, Analytic division; CDC, United States Centers for Disease Control and 
Prevention; EMR, Excess mortality rate; GBD, Global Burden of Disease Study; GHE, WHO 
Global Health Estimates; GLaMOR, Global Pandemic Mortality Project II; IHME, Institute 
for Health Metrics and Evaluation; LRI, Lower respiratory infections; PAF, Population 
attributable fraction; WHO, World Health Organization.  
MANUSCRIPT  
Seasonal influenza epidemics contribute significantly to global mortality, annually (1). The 
availability of influenza-associated burden estimates, especially in resource-limited settings 
(2), can support evidence-based policy decisions by guiding funding priorities for prevention 
and control, such as influenza vaccine introduction or expansion of existing immunization 
programmes (3), or availability and use of antiviral medications (4).   
National estimates of influenza-associated deaths may use different outcomes. Some studies 
will utilize ecological models beginning with all respiratory coded deaths to calculate 
influenza-associated excess deaths by substracting out deaths that are unlikely to be 
associated with an influenza virus infection (i.e., chronic respiratory deaths included in the 
baseline death calculation). Other groups might use a multiplier approach, beginning with 
lower respiratory infection (LRI) deaths and assign a proportion of those to influenza.   
Previous global influenza-associated mortality estimates from the World Health Organization 
(WHO) were widely referenced, despite lack of documentation on the methodology and data 
sources (5). In parallel, the increased number of countries with high quality influenza viral 
surveillance data and national disease mortality registries highlighted a need to update global 
estimates and document methods.  
Prior to updating global influenza-associated mortality estimates, WHO convened a 
consultation to compare the three recent global influenza mortality projects from: 1) United 
States Centers for Disease Control and Prevention (CDC), 2) the Netherlands Institute for 
Health Service Research, and 3) the Institute for Health Metrics and Evaluation (IHME).  
These groups used slightly different outcomes measures to arrive on global estimates.   
CDC led a collaboration of more than 47 countries to estimate global seasonal influenza-
associated deaths, focusing on respiratory mortality (6). The Netherlands Institute for Health 
Service Research, in collaboration with the US National Institutes of Health and CDC, 
conducted the Global Pandemic Mortality Project II (GLaMOR), funded by the WHO (7), to  
estimate global seasonal influenza-associated respiratory mortality. IHME leads the Global 
Burden of Disease (GBD) Study, funded by Bill & Melinda Gates Foundation. Estimates of 
LRI and aetiology-specific LRI mortality (influenza) from GBD 2016 were used in this 
comparison (8). 
We describe the different approaches to estimate global influenza mortality focusing on data 
sources, analysis, and model assumptions, and compare the differences between estimates.  
We compare methods and provide additional details regarding methodology to understand 
factors that may explain differences in these estimates and to make recommendations for 
future global burden efforts. 
Research group methods: description of the global models 
 
Table 1 summarises the approach taken by each research group. 
 
CDC model. 
CDC used a multi-step approach to extrapolate country-specific (185 countries/territories), 
regional, and global seasonal influenza-associated excess deaths, under the assumption that 
influenza burden scales with respiratory infection death rates (6). Deaths were estimated for 
1999-2015 and for three age groups (<65 years, 65- . First, they 
estimated influenza-associated excess mortality rates (EMRs) for 33 contributing countries or 
territories by applying time series linear regression models to weekly or monthly national 
vital statistics and viral surveillance data. Prior to extrapolation, Bayesian hierarchical models 
were used to calculate the mean influenza-associated EMR for the multiple years for each 
contributing country. These mean EMRs were applied to countries without data to estimate 
influenza-associated mortality.  For extrapolation, countries were divided into analytic 
divisions (ADs) using age-specific 2015 WHO Global Health Estimates (GHE) respiratory 
infection mortality rates . To adjust for differences in the risk of respiratory infection death 
between countries, country-specific respiratory mortality rate ratios were calculated by 
comparing GHE respiratory infection mortality rates from countries without EMR estimates 
to those with estimates. Extrapolation was conducted within each age-specific AD and 
uncertainty was quantified via 5,000 Markov Chain Monte Carlo simulations for each 
country. For the 33 contributing countries, extrapolated estimates were replaced by the mean 
influenza-associated EMR provided by the country.  
 
 
GLaMOR model. 
The GLaMOR model used a two-stage approach to estimate global and region-specific 
influenza-associated repiratory mortality, using a multiple imputation method for 
extrapolation (9). They calculated seasonal influenza-associated death estimates for two age 
groups . In Stage 1, they used age-specific seasonal influenza-
associated EMRs from countries or subnational regions. Thirty-three countries contributed 
data, of which, 30 overlapped with CDC contributing countries. In Stage 2, GLaMOR 
extrapolated EMRs to 196 countries using a multiple imputation method which involved a 
data creation step, followed by a hierarchical regression modelling step. Ten broad country 
level indicators of development, demographics, or health were used to match countries in the 
data creation step.  
 
IHME model. 
In the GBD 2016, IHME estimated the number of LRI deaths directly attributable to 
influenza, using a twostep modelling approach. First, they estimated overall LRI mortality by 
23 age groups (0-6 days, 7-27 days, 28-364 days, 1-4 years, and then in 5 year increments), 
sex, location (195 countries), and year for 1980-2016 (10). LRI mortality was modelled in a 
Cause of Death Ensemble model (11). Next, they estimated the aetiology-specific LRI 
mortality using a counterfactual approach to calculate the population attributable fraction 
(PAF) for influenza, or the proportion of LRI that could be averted if exposure to influenza 
was eliminated. PAF for influenza was estimated by:  
PAF = Prop x (1-1/OR) 
where Prop is the proportion of influenza positive LRI cases and OR is the odds ratio of LRI 
given influenza detection (12). Additionally, the influenza mortality PAF was adjusted for the 
age-specific relative case-fatality rate of viral to bacterial pneumonia episodes.  
 
METHODS 
Comparison analysis methods 
 
Country- and age-specific influenza-associated respiratory mortality rates were provided by 
CDC, GLaMOR, and IHME 
the 183 countries common between the groups for this comparison. CDC and GLaMOR used 
2015 United Nations World Population Prospects and IHME used their own population 
estimates for 2015 (Web Figure 1). CDC provided death counts and rates and the 95% 
credible interval (95%CI), the 2.5 and the 97.5 intervals from the posterior Markov Chain 
Monte Carlo distribution. GLaMOR provided the mean death counts, rates, and the range 
(lowest to highest annual estimate) across estimated years. IHME provided death counts, 
rates, and the 95% uncertainty intervals (95%UI).  Given the different interval estimates 
provided, we compared the point estimates. Analysis were completed for 183 common 
countries and  age group.  
We compared influenza mortality rate estimates between CDC and IHME, CDC and 
GLaMOR, and IHME and GLaMOR by calculating the fold difference or rate ratios between 
country- and age-specific mortality rates.  We obtained coefficient of variation within a 
WHO region for the country- and age-specific mortality rates using the ratio of the standard 
deviation to the mean. Then, we compared between-country variability within the WHO 
regions for CDC, IHME, and GLaMOR. We calculated p
correlations by age group and WHO region. 
 
RESULTS 
Magnitude of difference in influenza mortality estimates 
 
Overall, global influenza-associated respiratory deaths and rates (per 100,000 population) 
overlapped between CDC (409,111; 95% CI: 291,243, 645,832; 5.6, 95% CI: 4.0, 8.8) and 
GLaMOR (389,213; range: 293,980, 518,230; 5.9, range: 4.0, 8.0) methods. In contrast, both 
CDC and GLaMOR influenza-associated death estimates were higher than IHME influenza-
attributed LRI deaths (58,193; 95%UI: 43,953, 74,175; 0.8, 95%UI: 0.6, 1.0), a difference of 
nearly 350,000 deaths (Table 2).   
Among those <65 years, CDC and GLaMOR estimated the highest mortality rates among 
African region countries, followed by the Eastern Mediterranean, South-East Asia, and 
European region countries (Web Figure 2 A, B). In comparison, the highest IHME influenza-
attributed LRI mortality rates for this age group were observed in the European and Eastern 
Mediterranean countries, then by African countries (Web Figure 2, C). For those <65 years 
and all countries, the median mortality rate was 1.6/100,000 population for CDC and 
GLAMOR and 0.5/100,000 population for IHME. Among those 65 years, CDC and 
GLaMOR estimates were higher, particularly among Americas, African, and South-East Asia 
region countries (Web Figure 3 A, B). The median mortality rate for all countries 
year age group was lowest for IHME (6.2/100,000), compared to CDC (46.0/100,000) and 
GLaMOR (40.4/100,000; Web Figure 3, C). The median all-age mortality rates were 
1.0/100,000 for IHME, compared with 5.4/100,000 and 4.2/100,000 for CDC and GLaMOR, 
respectively (Figure 1). Scatter plots comparing influenza-associated mortality rates shows 
the highest differences in the African region for CDC and IMHE as well as the CDC and 
GLaMOR models. The comparison of rates between IHME and GLaMOR is consistent 
across WHO Regions (Web Figure 4). 
Overall, fold differences comparing influenza mortality rate estimates were lowest between 
CDC and GLaMOR (Figure 2 A; Web Figure 5 A; Web Figure 6 A). Across all age groups, 
country-specific influenza rate fold differences were the highest in the South-East Asia and 
Eastern Mediterranean regions between CDC and IHME (Figure 2 B; Web Figure 5 B; Web 
Figure 6 B) and GLaMOR and IHME (Figure 2 C; Web Figure 5 C; Web Figure 6 C). 
Among those s, the influenza-assocaited mortality rate mean fold differences 
observed between CDC and IHME and GLaMOR and IHME were similar with 7.6 and 8.1, 
respectively (Web Figure 6 B, C).  
Across methods, the coefficients of variation for the influenza-associated mortality estimates 
were similar (Table 3), except among those <65 years in the European region where IHME 
had a higher coefficient of variation (3.5) compared to CDC (2.8) and GLaMOR (2.0).  
Among those , IHME had the smallest (2.4) coefficient of variation in the Western 
Pacific region. Comparing the groups, the mortality rate coefficient of variation within WHO 
Regions was consistent between CDC, IHME, and GLaMOR, with the largest coeffient of 
variation observed in the Western Pacific and the lowest coefficient of variation in the 
African region. 
Across age groups,  higher correlations for WHO Regions were observed between CDC and 
IHME estimates except in the African region, compared with correlations between GLaMOR 
and IHME estimates (Table 4).  
 
Potential reasons for differences between global influenza mortality estimates 
Data sources and processing. 
Different data sources and inclusion criteria were used by the groups. Thirty-three countries 
contributed EMR data to the CDC mortality by either providing weekly or monthly vital 
records of mortality data for all respiratory causes of death (International Classification of 
Diseases Codes 9: 460 519; International Classification of Diseases Codes 10: J00 J99) by 
three age groups and was analysed by CDC. Alternatively, countries provided  age- and 
country-specific influenza-associated respiratory mortality rates analysed by the collaborator. 
Viral surveillance data was utilized by 26 countries. Countries without sufficient viral 
surveillance data used a Serfling approach (13) and defined their influenza epidemic period 
using pneumonia and influenza mortality data or the limited viral surveillance data available. 
Rate estimates were calculated or provided for at least four years/seasons, excluding the 2009 
pandemic period. Mortality rate ratios were calculated to adjust for differences in the risk of 
death between countries using the 2015 WHO GHE respiratory infection mortality rates, 
which included estimates for both lower respiratory  (International Classification of Diseases 
Codes 10: J09 J22, P23, U04) and upper respiratory (International Classification of Diseases 
Codes 10: J00-J06) infection mortality. Population estimates were obtained from the United 
Nations World Population Prospects and from the United States Census Bureau mid-year 
population estimates for 2015. 
In Stage 1 of the GLaMOR approach, weekly respiratory deaths and viral surveillance data 
were used to calculate annual EMRs. Data from 33 countries were included; EMRs from 30 
of these were also used in the CDC model. Data were available for 2002-2011, excluding the 
2009 pandemic year from the analysis. EMR estimates from India and Kenya were not 
included because death codes were based on verbal autopsy assessment of respiratory cause 
of death, however these countries were included in the sensitivity analysis. Ten country 
indicators (Table 1) were used in Stage 2 analysis to account for differences between 
countries. 
In the IHME approach, a total of 801,600 LRI mortality data points from 161 countries were 
used in the modelling, including all available data from vital registration systems, verbal 
autopsy and surveillance systems. Non-specific causes of death, such as sepsis or heart 
failure, were reallocated to specific causes of death (8), including LRI, according to 
regression models designed to assign specific causes (14).  The PAF was used to attribute 
LRI deaths to influenza and was calculated using the proportion of LRI cases positive for 
influenza, which was estimated by modelling data from a systematic literature review.  There 
were 649 data points that informed this model, representing all age groups, 102 geographic 
locations, and years between 1990 to 2016. Of these, 349 (53.8%) were from inpatient 
populations and 392 (60.4%) used polymerase chain reaction diagnostic techniques (10). The 
value used to capture the odds of LRI given influenza detection came from one source (15). 
The PAF further was adjusted for the relative frequency of non-fatal versus fatal LRI 
episodes using a scalar from DisMod proportion models, and for the case-fatality rate of viral 
to bacterial pneumonia episodes by age. The data sources for the case-fatality adjustment 
factor were representative of Austria, Brazil, Mexico, USA (8). 
 
Comparison of data sources and processing. 
The first major difference between the groups are the underlying data sources used to 
estimate influenza mortality burden.  While CDC and GLaMOR estimated EMRs using vital 
records mortality data for all respiratory deaths and extrapolating these data to countries, 
IHME used GBD LRI deaths and applied a proportion to obtain influenza deaths in a country.  
IHME calculated the maximum number of LRI deaths and attributed some to influenza. The 
IMHE model assumes that one death can only be counted once and categorically attributes 
deaths to a single underlying cause, thus influenza-related LRI deaths in patients with other 
underlying causes were assigned to another caetegory of death. With this approach the sum of 
deaths does not exceed the overall global mortality and resulted in a significantly lower 
number of LRI deaths to attribute to influenza commpared with the other groups.  
Another difference between IHME and the other groups may be the use of the fraction of 
influenza-related respiratory deaths occurring outside the LRI envelope. In particular, deaths 
occurring after complications of severe influenza infection such as secondary bacterial 
infection or the exacerbation of underlying medical conditions, including chronic obstructive 
pulmonary disease (16, 17), were considered in CDC and GLaMOR approaches.  However, 
the IHME method would have assigned these deaths to a different cause. Considering that 3.2 
million people die from chronic obstructive pulmonary disease every year (18) and that 
people ill with influenza and underlying chronic respiratory conditions have a higher risk of 
severe outcomes (19), if the IHME method was adjusted to utlize broader mortality 
categories or allowing deaths to be assigned to more than one cause, their influenza-related 
estimates would likely increase.  
Additionally, the quality of source data for extrapolation models may contribute to 
differences. Both CDC and GLaMOR required high-quality vital records and viral 
surveillance data to estimate influenza-associated excess mortality from a small subset of 
countries, which were used to extrapolate global deaths. Both groups lacked EMRs the 
Eastern Mediterranean region and had few EMRs from the African and South-East Asia 
regions. Moreover, GLaMOR excluded two countries with verbal autopsy data, limiting the 
use of data from these countries to the sensitivity analysis. In contrast, IHME was more 
flexible on data inclusion, allowing verbal autopsy, vital registration, and surveillance data 
from 161 countries for modelling LRI deaths. The different approaches highlights the 
importance of balancing quality and geographical distribution of data. For example, 
influenza-associated mortality across sub-Saharan countries in the CDC and GLaMOR 
models, where the exclusion of Kenya from GLaMOR analysis may have underestimated the 
burden in the region or perhaps overestimated burden by including Kenya in the CDC model. 
More flexible inclusion criteria might increase the number of contributing countries, though 
may increase risk of introducing biases in the models (20) due to incomplete data or biased 
representation of the cause-specific mortality from representative national samples compared 
to inclusive national data. Detemrining the appropriate balance between additional data 
points, particularly from low- middle-income countries, the risk of bias the model, and the 
consideration of complete data versus imputed data requires further investigation. 
calculation of the PAF may benefit from more representative data, by 
age and geography. Specifically, the odds ratio used in the PAF calculation for all age groups 
was obtained from the Shi et al. meta-analysis, which focused on children aged <5 years. 
Also, the case-fatality rate ratio for viral/bacterial pneumonia, used as adjustment factor for 
the death PAF, was calculated from data for four countries, mainly from the Americas region, 
and applied to all countries. Limitations in data in calculating the PAF may lead to an under 
or over estimation of deaths in certain age groups and regions and may increase the 
uncertainty of the influenza mortality estimate.  
 
Modelling assumptions, statistical methods and addressing uncertainty.  
Additional potential reasons for differences in the influenza mortality estimates between the 
groups may be the diverse modelling assumptions and methods to manage statistical 
challenges in extrapolation.  
CDC categorized countries into analytic divisions using the 2015 WHO GHE respiratory 
infection mortality rates, which were ranked from lowest to highest and countries were 
distributed across three ADs, resulting in a total of nine age-specific ADs. Countries with 
variation in respiratory infection mortality between age groups could be classified into 
different analytic divisions for the age groups. The number of EMR-contributing countries 
within each AD ranged from 6 18 depending on categorization into the AD and available 
data. To validate the analytic divisions, authors performed different sensitivity analyses. 
When removing ADs, the range in mortality estimates became larger, supporting their 
assumption that ADs generate more conservative estimates and that estimating influenza 
deaths between countries with similar LRI mortality was appropriate.  
In the GLaMOR approach, a multiple imputation model was applied to each year between 
2002-2011 (excluding 2009). Mortality estimates provided by countries were used in the 
imputation for each year. If a contributing country did not have complete data for 2002-2011, 
the missing years were not filled in to ensure a complete group of contributing countries for 
each year. The Stage 2 analysis was performed for those years where data from 19 or more 
Stage 1 countries were available. Results of the sensitivity analysis, which included Stage 1 
input for India and Kenya, showed an important variation of the estimates in the <65 age 
group for those years where data from these two countries were included (7). 
In the IHME approach, a smoothing approach was used to calculate the proportion of LRI 
episodes that tested positive for influenza by five year increments starting in 1990. This 
approach does not capture single year heterogeneity in influenza circulation and may not be 
reliable in the event of large influenza outbreaks or implementation of preventative 
interventions. However, a significant epidemic can be included as an external factor after 
completing modelling, specifically for  the 2009 influenza A(H1N1) pandemic (21).  
Each  group had a different approach regarding the use of covariates in their models (Table 
1). CDC used GHE respiratory infection mortality estimates as a proxy to account for 
differences in mortality risk between countries and used these ratios to extrapolate influenza 
associated excess mortality rates from countries with available estimates to those without. 
GLaMOR selected 10 country-specific indicators to generate influenza-associated respiratory 
mortality for their Stage 2 analysis, including non-influenza related indicators (e.g., WHO 
Region). IHME method used 13 covariates to model LRI mortality in the Cause of Death 
Ensemble model (11), which is based on an algorithm that selects the most plausible 
biological relationship with LRI mortality (10). 
Each group described the uncertainty of their estimates using different approaches.  To 
describe the uncertainty in the age-specific influenza-associated respiratory death estimates 
for each country, CDC calculated 95% credible intervals from the posterior distribution 
generated from 5,000 extrapolation iterations, using different values for unknown parameters 
obtained from a Bayesian framework. IHME presented 95% uncertainty intervals, calculated 
from 1,000 draws the parameters in the PAF equation including LRI mortality, modelled 
proportions, odds ratios, and case-fatality rate scalars. GLaMOR presented the variability in 
mortality over time as a range (minimum and maximum) of the annual influenza-associated 
mortality estimates rather than a statistical interval estimate. 
 
Comparison of modelling assumptions, statistical methods and addressing uncertainty. 
Differences in modelling strategy also contributed to the variation in the estimates between 
the groups. This is particularly noteable between CDC and GLaMOR models, where despite 
the use of similar EMR data, the modelling approaches generated different results. Further, 
including data from India and Kenya to the GLaMOR model may have increased their 
estimates and potentially making their maximum values more similar to the credible intervals 
presented by CDC. In addition, imputing missing season/year rate estimates for contributing 
countries could have reduced the year-to-year fluctuation of EMRs observed in the sensitivity 
analyses in the GLaMOR project (7). 
The use of smoothing processes in IHME models limits the ability to evaluate yearly 
variation of influenza burden. Similarly, the CDC estimates represent a mean mortality rate 
over the time period from 1999-2015. The GLaMOR approach, which imputed EMRs for 
each influenza season, allows for better evaluation of annual fluctuations in influenza burden 
because of changes in virus circulation. 
The use of covariates in modelling is common to improve estimate precision; however, 
covariates may also introduce bias when imputing or extrapolating to generate estimates. 
Covariate selection is especially important in absence of high quality input data (20) for 
models.While the groups considered several covariates, none of the covariates used were 
common among the models, potentially contributing further to the differences in the 
estimates. 
 
DISCUSSION 
Although time-series models are commonly used to estimate influenza-associated mortality, 
these estimates could lead to under or over estimates of influenza mortality (20, 22). Further, 
it is not feasible for all countries to use these methods due to lack of reliable data. Methods to 
estimate influenza-associated mortality that can be used by more countries is not available 
(23), though needed. Efforts by CDC, GLaMOR, and IHME help to fill this gap in influenza 
burden knowledge by calculating country-specific, regional, and global influenza-associated 
mortality estimates. By contributing to this comparison, these groups assist in developing a 
better understanding of differences in estimates and reasons behind those differences. 
As demonstrated by these groups, global influenza mortality burden can be conceptualised 
and presented using different methods. While CDC and GLaMOR mainly focused on 
defining the number of influenza respiratory deaths, IHME measured only influenza-
attributable deaths within LRI mortality. By modelling respiratory excess mortality, CDC and 
GLaMOR estimated those deaths that may be associated with influenza, while IHME through 
a counterfactual approach estimated LRI deaths caused by influenza. As expected given the 
similarity of the approach and use of all respiratory deaths, the CDC and GLaMOR models 
generated similar overall estimates. Given that IHME started from a more restrictive 
mortality outcome (LRI deaths), their estimates were four to five times lower than the others. 
However, reassuringly, ranking the estimates across regions and age groups showed similar 
variability in some cases, suggesting true differences in disease burden rather than modeling 
artifacts.  
Complete transparency of the modelling approach and openness to refine future estimates has 
been a fundamental component of this joint collaboration. The commitment to further 
improve modelling approaches by IHME were documented in the recent GBD 2017 
publication (18). A revision of the ratio of mortality in viral compared to bacterial causes of 
LRI death resulted in a two-fold increase of LRI deaths attributable to influenza (24). 
Accurate quantification of influenza mortality is challenging because several factors may 
contribute to differences in modelled estimates including source data quality,  parameter and 
covariate choice, and modelling assumptions. The variability of several parameters across the 
groups made it difficult to identify which aspects of the models drove the observed 
differences. A standard approach to assess data quality and suitability for global modelling 
and the use of common covariates might reduce differences across the estimates. Thus, the 
remaining differences being related to the actual model selected. Continued collaboration 
between modelling groups and sharing of data could improve geographic representation in 
future global models and improve validation and enhancement of methods.  
The review of these global influenza mortality efforts provided WHO with necessary 
information for a consensus on the newly adopted WHO influenza-associated respiratory 
mortality estimate (4). Though, the true burden of influenza is expected to be higher when 
taking into consideration influenza-associated deaths that exacerbate non-respiratory 
conditions, such as cardiovascular diseases. To achieve greater understanding of the true 
burden of influenza mortality, a continued collaboration between groups may promote further 
improvements in methodology, greater appreciation for strengths and weaknesses of the 
different approaches, and possibly convergence over time in global mortality estimates. 
 
 
 
Disclaeimer: The findings and conclusions in this report are those of the authors and do not 
necessarily represent the official position of the World Health Organization, and the Centers 
for Disease Control and Prevention. 
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Table 1. Description of CDC, GLaMOR and IHME Models to Estimate Influenza Respiratory Mortality 
 
 Research 
group 
Envelope Sources of data Age groups (years) Indicators Extrapolation Methodology 
CDC a 
All respiratory 
causes of death 
EMRs from 33 countries or 
territories. 
 
Annual respiratory deaths from 
14 countries. 
 
WHO GHE RI deaths, 2015. 
 
United Nations and United 
States Census Population 
Estimates 2015 b. 
 
Study period: 1999 2015. 
<65, 65-
All 
WHO GHE RI deaths (2015) as a proxy to 
account for differences in MMR 
 
Bayesian Hierarchical Model with Multiplier 
Estimate country-specific influenza-associated respiratory EMR for 33 
countries using time series log-linear regression models with vital death 
records and influenza surveillance data. 
 
Extrapolate estimates to countries without data. Countries divided into 
three ADs using WHO GHE RI mortality rates. 
 
Country-specific MRR generated from WHO GHE RI deaths 
Random average country-specific mortality rate from a contributing 
country multiplied by country/specific MMR to calculate country-specific 
mortality rate distributions 
GLaMORc 
All respiratory 
causes of death 
EMRs from 33 countries or 
territories. 
 
Study period: 2002-2011. 
 
10 country-specific indicators:  
WHO region; age group all-cause mortality 
rates; physician density; obesity; population 
density; major infectious diseases; Gross 
National Income per capita; rural population; 
population age structure; latitude 
Multiple Imputation Method for extrapolation 
Two-step approach with a data creation step (Stage 1) followed by a 
hierarchical regression modeling step to project burden for all countries 
(Stage 2). 
 
For data creation, used statistical correlations between country-specific 
indicators and contributing country mortality estimates to create 
distribution of possible mortality values. 
IHMEd LRI deaths 
LRI mortality data from 10,312 
site-year vital registration, 915 
site-year verbal autopsy, and 928 
site-year surveillance data, 
between 1980 and 2016. 
23 age groups  
(0-6 days, 7-27 
days, 28-364 days, 
1-4 years, and every 
5 years up to 99) 
13 covariates involved in the modelling 
process of LRI mortality: 
Pneumococcal conjugate vaccine coverage; 
indoor air pollution; LRI Summary Exposure 
Variable; Mean BMI; Smoking prevalence; 
DTP3 vaccine coverage; Healthcare access 
and quality index; Education per capita; LDI 
per capita; Socio-demographic index; Alcohol 
liters per capita; Outdoor air pollution 
(PM2.5); Water and sanitation SEV. 
 
Counter-Factual Approach to Attribute Influenza 
Estimate of LRI deaths. 
Attribution of specific pathogens (influenza) by: 
Systematic review to estimate prevalence of influenza virus in 
patients with LRI; 
Calculation of PAF using proportion influenza positive and OR of 
LRI given the presence of influenza virus; 
Attributable fraction adjusted by the viral: bacterial pneumonia 
CFR ratio. 
Abbreviations: AD, analytic divisions; CDC, United States Centers for Disease Control and Prevention; CFR, case-fatality rate; EMR, excess mortality estimates; GLaMOR, Global Pandemic Mortality Project; IHME, 
Institute for Health Metrics and Evaluation; LRI, lower respiratory tract infection; MMR, mortality risk between countries; MRR, mortality rate ratio; PAF, population attributable fraction; RI, respiratory tract 
infection; URI, respiratory tract infection; WHO GHE, WHO Global Health Estimates. 
aIuliano AD et al. (6); bUN World population prospects. (25); c Paget J et al. (7); dGBD 2016 Causes of Death Collaborators. (8). 
 
 
Table 2. Global Influenza-Associated Mortality Estimates by Age Group 
 
   CDCa GLaMORb  IHMEc 
 Age Group 
Median 95%CI 
Rates          
per 100,000 
 95%CI 
Median 
Ranged 
Rates 
per 100,000 
 Rangea Median 95%UI 
Rates         
per 100,000 
95%UI 
All Ages 409,111 291,243, 645,832 5.6 4.0, 8.8 
389,213 
293,980, 518,230 
5.9 4.0, 8.0 58,193 43,953, 74,175 0.8 0.6, 1.0 
< 65 years 175,303 67,255, 342,576 2.6 1.0, 5.1 
128,512 
91,764, 184,980 
2.1 1.6, 3.1 30,041e 13,019, 60,297 0.4e 0.2, 0.9 
 244,012e 188,261, 330,694 40.2e 31.0, 54.5 
260,701 
187,430, 333,250 
53.7 35.6, 71.7 27,884e 13,718, 49,871 4.6e 2.3, 8.3 
 
Abbreviations: CDC, United States Centers for Disease Control and Prevention; CI, credible interval; GLaMOR, Global Pandemic Mortality Project; IHME, Institute for Health Metrics and Evaluation; UI, uncertainty 
interval. 
aIuliano AD et al. (6); bPaget J et al. (7); cGBD 2016 Causes of Death Collaborators. (8); dRange, minimum and maximum annual rates;eEstimates for these age groups were not included in publications. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Coefficients of Variation for the Country-specific Influenza-Associated Mortality Estimates by WHO Region and Age Group  
 
WHO 
Region 
< 65 years  All Ages 
CDC GLaMOR IHME CDC GLaMOR IHME CDC GLaMOR IHME 
AFRO 1.51 1.60 1.24 1.48 1.54 1.25 1.49 1.57 1.23 
AMRO 1.76 1.60 2.27 2.18 2.37 2.25 2.00 2.12 2.20 
EMRO 1.82 1.53 1.77 1.27 1.64 1.55 1.53 1.58 1.66 
EURO 2.79 2.00 3.52 1.64 1.62 1.62 1.71 1.65 2.54 
SEARO 1.90 2.16 2.28 2.42 2.05 2.57 2.11 2.10 2.41 
WPRO 2.65 3.39 2.21 3.75 3.61 2.43 3.56 3.56 2.27 
Abbreviations: AFRO, African Region; AMRO, Region of the Americas; CDC, United States Centers for Disease Control and Prevention; EMRO, Eastern Mediterranean Region; EURO, European Region; GLaMOR, 
Global Pandemic Mortality Project; IHME, Institute for Health Metrics and Evaluation; SEARO, South-East Asia Region; WPRO, Western Pacific Region. 
 
 
 
 
Ranked Correlations of Influenza-Associated Mortality Estimates by WHO Region and Age Group 
 
 
WHO 
Region 
<65 years  All Ages 
CDC - IHME CDC - GLaMOR GLaMOR- IHME CDC - IHME CDC - GLaMOR GLaMOR- IHME CDC - IHME CDC - GLaMOR GLaMOR- IHME 
AFRO -0.12 0.09 0.48 0.01 -0.03 0.42 0.15 0.48 0.40 
AMRO 0.62 0.56 0.57 0.64 0.66 0.60 0.65 0.62 0.52 
EMRO 0.85 0.72 0.82 0.67 0.29 0.53 0.83 0.73 0.61 
EURO 0.73 0.78 0.60 0.37 0.30 -0.01 0.14 0.45 -0.15 
SEARO 0.32 0.74 0.71 0.80 -0.47 -0.35 0.72 0.13 0.52 
WPRO 0.67 0.84 0.76 0.61 0.60 0.40 0.38 0.44 0.28 
 
Abbreviations: AFRO, African Region; AMRO, Region of the Americas; CDC, United States Centers for Disease Control and Prevention; EMRO, Eastern Mediterranean Region; EURO, European Region; GLaMOR, 
Global Pandemic Mortality Project; IHME, Institute for Health Metrics and Evaluation; SEARO, South-East Asia Region; WPRO, Western Pacific Region. 
Figure 1. Country-Specific Influenza Respiratory Mortality Rates by Quartile, All Ages 
 
A) CDC, United States Centers for Disease Control and Prevention; B) GLaMOR, Global Pandemic Mortality Project; C) IHME, Institute 
for Health Metrics and Evaluation. 
Mortality Rate per 100,000 population. Rates for 183 countries included. Lighter colors indicate a lower mortality rate. 
 
 
 
Figure 2. Fold Differences Comparing Pairwise Influenza Mortality Rate Estimates by Quartile, All Ages 
 
A) CDC versus GLaMOR; B) CDC versus IHME; C) GLaMOR versus IHME. Abbreviations: CDC, United States Centers for Disease 
Control and Prevention; GLaMOR, Global Pandemic Mortality Project; IHME, Institute for Health Metrics and Evaluation. 
Rates for 183 countries included. Lighter colors indicate a low fold difference. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
